Jiangsu Hengrui Explained

Jiangsu Hengrui Pharmaceuticals Co. Ltd
Logo Upright:0.9
Foundation:1997
Location:Lianyungang, Jiangsu, China
Industry:Pharmaceuticals
Num Employees:24,500 (2020)
Type:Public company
Key People:Sun Piaoyang (chairman)

Jiangsu Hengrui Pharmaceuticals Company Ltd., also known as Jiangsu Hengrui, is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products.[1] [2] It is the largest listed pharmaceutical company in China.[3]

History

Founded in 1970, Jiangsu Hengrui Pharmaceuticals was originally state-owned and called Lianyungang Pharmaceutical Factory .[4] [5] Headquartered in Lianyungang, Jiangsu, it was established in its current form in 1977. The company was listed on the Shanghai Stock Exchange in 2000[6] and now has locations in China, the United States, Germany, Switzerland, Japan, and Australia.

Research and development

In 2020, Jiangsu Hengrui Pharmaceuticals set up research and development offices in Princeton, New Jersey, and in Basel, Switzerland.[7] [8] The Swiss-based Hengrui Europe Therapeutics AG also hosts the discovery research and development units. Their focus is on protein engineering and the mRNA technology platform.

Since December 2020, Jiangsu Hengrui Pharmaceuticals has run clinical trials on anti-cancer drugs such as:

Trials were also performed in the fields of metabolic diseases (e.g., type 2 diabetes[13]), autoimmune diseases (Interleukin-17 receptor blocker vanucizumab in psoriasis), HIV treatment, and analgesia.

See also

External links

Notes and References

  1. https://www.reuters.com/companies/600276.SS Profile of Jiangsu Hengrui Medicine Company Limited
  2. Web site: Search of: Hengrui - List Results - ClinicalTrials.gov. 22 November 2020. clinicaltrials.gov. en.
  3. https://www.cnbc.com/2018/04/19/chinas-pharmaceutical-industry-is-poised-for-major-growth.html China's pharmaceutical industry is poised for major growth
  4. News: Sun Piaoyang . 6 February 2021 . Forbes . en.
  5. News: 中国最牛"夫妻店"：日赚2亿，一人一家上市公司，掌管2500亿！ . 6 February 2021 . finance.sina.cn . 13 December 2020 . https://web.archive.org/web/20210206125804/https://finance.sina.cn/2020-12-13/detail-iiznctke6287466.d.html. 6 February 2021.
  6. Web site: Company Profile . 8 January 2020 . 28 October 2020 . https://web.archive.org/web/20201028222254/https://www.hrs.com.cn/hren/about_organize.html . dead .
  7. Web site: Hengrui Medicine sets up clinical research and development in Basel. 22 November 2020. Basel Area Business & Innovation. en-US.
  8. Web site: Entry in commercial registry "Handelsregisteramt des Kantons Basel-Stadt". 22 November 2020. www.zefix.ch.
  9. Web site: Search of: camrelizumab - List Results - ClinicalTrials.gov. 30 December 2020. clinicaltrials.gov. en.
  10. Web site: Search of: SHR-3680 - List Results - ClinicalTrials.gov. 30 December 2020. clinicaltrials.gov. en.
  11. Web site: Search of: SHR-3162 - List Results - ClinicalTrials.gov. 30 December 2020. clinicaltrials.gov. en.
  12. Web site: Search of: SHR-3162 - List Results - ClinicalTrials.gov. 30 December 2020. clinicaltrials.gov. en.
  13. Jiangsu HengRui Medicine Co., Ltd.. 9 December 2020. Evaluation of the Efficacy and Safety of INS068 Injection and Insulin Degludec Subcutaneous Injection Once Daily in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With One or Two Oral Antidiabetics (A Randomized, Open-Label, Two-Arm, Treat-to-Target, Parallel Controlled Trial).

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Jiangsu Hengrui".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.